Figure 1. Mechanisms/pathways underlying tumor dormancy.
| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website https://www.wjon.org |
Review
Volume 13, Number 1, February 2022, pages 8-19
Tumor Dormancy: Biologic and Therapeutic Implications
Figure
Table
| Topics | Study | Year |
|---|---|---|
| Role of the niche | ||
| Self-renewal of cancer stem cells by asymmetric cell division; Active and dormant cancer cells stages are reversible. | Lawson [8] | 2015 |
| Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. | Shiozawa [10] | 2011 |
| Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. | Vora [11] | 1994 |
| A pilot, exploratory, randomized, phase II safety study evaluating tumor cell mobilization and apheresis product contamination in patients treated with granulocyte colony-stimulating factor alone or plus plerixafor | Nahi [12] | 2019 |
| CXCR4 is required for the quiescence of primitive hematopoietic cells. | Nie [13] | 2008 |
| Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. | McCabe [14] | 2007 |
| Self-renewal of cancer stem cells by asymmetric cell division. Active and dormant cancer cells stages are reversible | Lawson [8] | 2015 |
| Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. | Taichman [15] | 2002 |
| Involvement of chemokine receptors in breast cancer metastasis. | Muller [16] | 2001 |
| Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone | Price [17] | 2016 |
| Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. | Shiozawa [18] | 2008 |
| GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. | Shiozawa [19] | 2010 |
| Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow. | Yumoto [20] | 2016 |
| Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. | Boyerinas [21] | 2013 |
| Advances in targeting DTCs and CSCs | ||
| Chemoresistant DTCs occupy the perivascular niche (PVN) of distant tissues protected from ER | Carlson [23] | 2019 |
| Self-renewal of cancer stem cells by asymmetric cell division. Active and dormant cancer cells stages are reversible | Lawson [8] | 2013 |
| Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. | Boyerinas [21] | 2013 |
| Human prostate cancer metastases target the hematopoietic stem cell niche. | Shiozawa [10] | 2011 |
| Breast tumor dormancy regulated by perivascular niche. | Ghajar [9] | 2013 |
| Breast cancer metastatic relapse due to proteins E-selectin and CXCL12+ to anchor cancer cells to perivascular niches in the bone marrow | Price [17] | 2016 |
| Single cell RNA sequencing of rare immune cell populations | Nguyen [25] | 2018 |
| Spatial transcriptomics coming of age | Burgess [26] | 2019 |
| Metastasis prevention by targeting the dormant niche | Ghajar [27] | 2015 |
| Inhibition of EIF2α dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy | Schewe [28] | 2009 |
| MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents | Fan [29] | 2011 |
| Dormancy programs as emerging antimetastasis therapeutic alternatives | Sosa [30] | 2016 |
| Glycolysis inhibition for anticancer treatment | Pelicano [31] | 2006 |
| Targeting hypoxia in cancer treatment | Wilson [32] | 2011 |
| NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes | Sosa [33] | 2015 |
| Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement | Johnson [34] | 2018 |
| A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. | Khoo [35] | 2019 |
| The history and future of targeting cyclin-dependent kinases in cancer therapy | Asghar [36] | 2015 |
| VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors | Lu [24] | 2011 |
| Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) | Coleman [37] | 2018 |
| Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomized open-label phase 3 trial | Coleman [38] | 2014 |
| Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy | Black [39] | 1993 |
| Molecular mechanisms underlying tumor dormancy | Almog [5] | 2010 |
| Targeting leukemic stem cells by breaking their dormancy | Essers [40] | 2010 |
| ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease | Sosa [41] | 2011 |
| Mechanisms of disseminated cancer cell dormancy: an awakening field | Sosa [22] | 2014 |